Key players in Substance Use Disorder Treatment
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 | Indivior | — | 66 reports |
| 2 | Alkermes | — | 66 reports |
| 3 | Acadia Healthcare | — | 66 reports |
| 4 | Orexo | — | 66 reports |
| 5 | BICYCLE Health | — | 33 reports |
Also active in Substance Use Disorder Treatment
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
| Company | Where public records show them |
|---|---|
 Eli Lilly and Company |
|
| Afasci Inc |
|
| Spark Biomedical, Inc. |
|
| Square2 Systems, Inc. |
|
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Top trial sponsors in Substance Use Disorder Treatment
Companies leading the most active studies found with this market's trial search, worldwide (key players included).
- Eli Lilly and Company 3 active trials on ClinicalTrials.gov (opens in a new tab)
- Afasci Inc 2 active trials on ClinicalTrials.gov (opens in a new tab)
- Spark Biomedical, Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)
- Square2 Systems, Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)
Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Substance Use Disorder Treatment reports by place
Australia
Brazil
Canada
China
Ecuador
Egypt
France
Germany
Hong Kong
India
Italy
Japan
Kenya
Malaysia
Mexico
New Zealand
PhilippinesGet the full Substance Use Disorder Treatment report
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.